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MALT1 paracaspase is activated upon antigen
receptor stimulation to promote lymphocyte acti-
vation. In addition, deregulated MALT1 protease
activity drives survival of distinct lymphomas such
as the activated B cell type of diffuse large B cell
lymphoma (ABC-DLBCL). Here, we designed fluoro-
phore or biotin-coupled activity based-probes (ABP)
that covalently modify the active center of MALT1.
MALT1-ABPs are exclusively labeling an active
modified full length form of MALT1 upon T cell stim-
ulation. Further, despite the CARMA1 requirement
for initial MALT1 activation, the MALT1-ABPs show
that protease activity is not confined to the high-
molecular CARMA1-BCL10-MALT1 (CBM) complex.
Using biotin-coupled ABPs, we developed a robust
assay for sensitive and selective detection of active
MALT1 in cell lines, primary lymphocytes, and
DLBCL tumor biopsies. Taken together, MALT1-
ABPs represent powerful chemical tools to mea-
sure cellular MALT1 activation, determine efficacy
of small molecule inhibitors, and classify lymphomas
based on MALT1 activity status.
INTRODUCTION
MALT1 paracaspase is part of the CARMA1-BCL10-MALT1
(CBM)-complex that connects proximal antigen receptor
signaling to the IkB kinase complex to induce the canonical
NF-kB pathway (Paul and Schaefer, 2013; Thome et al., 2010).
The central paracaspase domain of MALT1 forms an active
site with a catalytic dyad of cysteine 464 and histidine 415 that
is structurally highly homologous to classical caspases (Wies-
mann et al., 2012; Yu et al., 2011). In contrast to most caspases,
MALT1 does not require an autoproteolytic cleavage reaction
for activation and displays a high preference for arginine in theChemistry & Biology 22, 129position 1 (P1) (Hachmann et al., 2012). Therefore, cleavage
activity resembles metacaspases that are exclusively found in
protozoa, fungi, and plants, and thus MALT1 confers a unique
proteolytic activity in mammals (Uren et al., 2000).
In resting cells, MALT1 is in an inactive state and its activity is
rapidly induced upon T cell receptor (TCR)/CD28 costimulation.
By cleaving signaling regulators like BCL10, A20, CYLD, RelB,
and Regnase-1, MALT1 enzymatic activity is necessary for
optimal T cell activation in response to TCR/CD28 stimulation
(Coornaert et al., 2008; Du¨wel et al., 2009; Hailfinger et al.,
2011; Rebeaud et al., 2008; Staal et al., 2011; Uehata et al.,
2013). Activation of MALT1 depends on conformational changes
within the paracaspase and the C-terminal Ig3 domains
(Wiesmann et al., 2012), but the mechanisms of cellular activa-
tion are not completely understood. Binding of MALT1 to
CARMA1-BCL10 filamentous structures can accelerate MALT1
activation (Qiao et al., 2013). In addition, mono-ubiquitination
of MALT1 in the C-terminal Ig3 domain is an essential step for
stimulus dependent MALT1 activation (Pelzer et al., 2013). How-
ever, the lack of tools to selectively stain active MALT1 paracas-
pase has precluded an analysis of modifications and complexes
involved in initiating and maintaining an active MALT1 in cells.
MALT1 protease represents a promising therapeutic target.
MALT1 deficiency protects mice from experimental autoim-
mune encephalomyelitis (EAE), and MALT1 activity is enhanced
in T cells from EAE mice (Bru¨stle et al., 2012; Mc Guire et al.,
2013). Thus, MALT1 inhibition may be used to treat autoim-
mune diseases like Multiple Sclerosis. Constitutive MALT1 ac-
tivity delivers a critical survival signal in distinct lymphomas.
The activated B cell type of diffuse large B cell lymphoma
(ABC DLBCL) relies on chronic B cell receptor (BCR) signaling
that triggers MALT1 activity (Ferch et al., 2009; Hailfinger et al.,
2009). Further, constitutive MALT1 activation of the API2-
MALT1 fusion protein drives noncanonical NF-kB in mucosa
associated lymphoid tissue (MALT) lymphoma (Rosebeck
et al., 2011). First, small molecule MALT1 inhibitors have
been identified that selectively kill ABC DLBCL tumors in vitro
and in vivo (Fontan et al., 2012; Nagel et al., 2012), but a
reliable tool to detect MALT1 in different lymphoma entities is
missing.–138, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 129
AB
Figure 1. Synthesis of AOMK Probes 2 and
5–7
(A) Construction of the tetrapeptide part on
chlorotrityl resin followed by AOMK installation in
solution.
(B) Solid phase synthesis of the probe on resin
starting from bound AOMK building block.
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Detection of Active MALT1 in CellsActivity-based probes (ABPs) achieved great importance in
studying enzyme activities in their cellular context, as well as
in pathological settings (Blum et al., 2007; Greenbaum et al.,
2002c; Nomura et al., 2010; Paulick and Bogyo, 2008). ABPs
distinguish between active and inactive enzymes, often by a
mechanism-based reaction with a reactive electrophile, which
attacks the catalytic site to arrest the active state of an enzyme.
A detection marker such as a fluorophore or a biotin is used
for monitoring enzyme activity in subsequent assays (Cravatt
et al., 2008; Heal et al., 2011; Serim et al., 2012). For cysteine
proteases like cathepsins and caspases, ABPs were applied for
gel-based or mass spectrometry profiling, inhibitor screening,
and imaging (Blum et al., 2005; Greenbaum et al., 2002a).
To date, measurement of cellular MALT1 activity relies
on in vitro protease activity assays after immunprecipitation or
indirectly by the detection of cleaved substrates (Coornaert
et al., 2008; Kloo et al., 2011; Rebeaud et al., 2008). Both
methods are unable to monitor active MALT1 directly in the
cellular context. Here, we use a chemical approach that allows
a rapid, sensitive, and selective detection of active cellular
MALT1 by ABPs. We use these ABPs to profile cellular MALT1
activity in T cells and lymphomas.
RESULTS
Chemical Synthesis and Validation of MALT1-ABPs
The design of theMALT1-ABPs was based on the acyloxymethyl
ketone (AOMK) electrophile that is attacked by the catalytic
cysteine, forming a covalent bond. AOMKs are known for
their high specificity for cysteine proteases, and their very low
background signal (Kato et al., 2005). As specific recognition
element, we chose the tetrapeptide sequence leucine-arginine-
serine-arginine (LRSR) derived from the MALT1 cleavage site
in BCL10, which was shown to be one of the best MALT1
substrate sites (Hachmann et al., 2012). As a detection handle,
we introduced an alkyne (probe 2), fluorescein isothiocyanate130 Chemistry & Biology 22, 129–138, January 22, 2015 ª2015 Elsevier Ltd All rights reserve(FITC) (probe 5), boron-dipyrromethene
(BODIPY)-FL (probe 6), or biotin (probe
7) (Figures 1 and 2A). We followed two
chemical routes for the successful syn-
thesis of the ABPs (Blum et al., 2005;
Kato et al., 2005). In the first route (Fig-
ure 1A), the peptide part was constructed
on a chlorotrityl resin. After cleavage, the
C-terminal carboxylic acid was subse-
quently converted into an AOMK by a
three step sequence to yield the desired
probe 2 (alkyne-LRSR-AOMK). In the
second synthetic approach (Figure 1B),
we first attached the arginine AOMKbuilding block to the solid phase through a hydrazone linkage
(compound 3) and then elongated the peptide by deprotecting
the fluorenylmethoxycarbonyl group (Fmoc) with tetrabutylam-
monium fluoride (TBAF). This route led to the successful isolation
of FITC- (probe 5), BODIPY-FL- (probe 6), and BiotinK- (probe 7)
LRSR-AOMK (Figures 1 and 2A; see Supplemental Experimental
Procedures, available online, for details).
To verify the action of the probes on MALT1, we cocrystallized
human MALT1Casp-Ig3 in complex with probe 2 (Figure 2B;
Supplemental Experimental Procedures). Alkyne-LRSR-AOMK
covalently modified the active site cysteine 464 of MALT1. Over-
all, probe 2 induced similar conformational rearrangements
reported for the VRPR-fluoromethyl ketone (FMK) peptide bound
to MALT1 (Wiesmann et al., 2012). However, in contrast to
VRPR, the LRSR bound crystal structure possesses a slightly
better ordered L4 substrate binding loop (Figure S1A), which
may explain the reported preference for a leucine in the P4
position (Hachmann et al., 2012). The data underscore that the
specific LRSR recognition peptide and the AOMK warhead are
well suited for the generation of MALT1-ABPs.
Detection of Active Cellular MALT1 by Fluorophore-
Coupled ABPs
Alkynes are amenable for tandem labeling by a copper(I)-cata-
lyzed alkyne-azide-cycloaddition, also called click chemistry
(Speers et al., 2003). We produced tetramethylrhodamine acid
(TAMRA)-labeled probe 2 by click chemistry. First, we analyzed,
if our MALT1-ABP forms an irreversible complex with active
MALT1, which can be detected in a gel-based assay by fluores-
cence scanning. Indeed, overexpressed FLAG-MALT1 wild-
type (WT), but not the catalytic inactive mutant FLAG-MALT1
C464A, was detected by TAMRA-probe 2 after FLAG immuno-
precipitation (IP) in Jurkat T cells (Figure S1B). Probe 2 labeling
of active MALT1 exactly matched the results obtained from
A20 substrate cleavage after FLAG-MALT1 overexpression
(Figure S1C). Notably, overexpression of MALT1 was sufficientd
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Figure 2. Design, Crystallization, and Active
Cellular MALT1 Detection by MALT1-ABP
(A) Overview of MALT1 ABPs.
(B) Probe 2 (alkyne-LRSR-AOMK) cocrystallizes
with MALT1Casp-Ig3 (Protein Data Bank entry 4I1P).
Close up view of the MALT1 active site with the
peptide inhibitor alkyne-LRSR-AOMK depicted
as yellow stick model and shown in standard
orientation.
(C) Extracts of Jurkat T cells were stained with
the MALT1-ABP probe 5 (3 mM). After SDS-PAGE
and fluorescence scanning, MALT1-ABP complex
in stimulated cells was visualized. MALT1 inhi-
bitors (10 mM) prevent MALT1-ABP binding; open
circle indicates cathepsin B labeling.
(D) MALT1-ABP labeling in extracts of Jurkat
T cells, transfected with small interfering (si) RNA
against MALT1 and siGFP as control for 72 hr.
Knockdown was checked by western blot.
(E) Extracts of primary human PBMCs and T cells
(1 3 107 cells) were labeled with probe 5.
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Detection of Active MALT1 in Cellsto induce MALT1 activation in all assays even in the absence
of phorbol 12-myristate 13-acetate (PMA)/Ionomycin (P/I)
stimulation.
To analyze active endogenous MALT1 in Jurkat T cells, we
used ABP probe 5 in which LRSR-AOMK was directly coupled
to FITC. Whole cell lysates of anti-CD3/CD28 or P/I treated
Jurkat T cells were labeled with probe 5 to investigate the
specificity of the probe. Endogenous active MALT1-probe 5
complexes were exclusively detected after T cell stimulation
(Figures 2C and 2D). No labeling of endogenous MALT1 was
obtained in the absence of stimulation and, despite some back-
ground staining, MALT1 was the only inducible signal upon
stimulation. Specific labeling of MALT1 was confirmed by the
severe reduction of the MALT1-ABP complex after MALT1
knockdown (Figure 2D). In addition, MALT1 staining was
reduced upon preincubating the cells with the covalent, active
site MALT1 inhibitor z-VRPR-FMK or the allosteric, reversible
MALT1 inhibitors mepazine or thioridazine (Figure 2C) (Rebeaud
et al., 2008; Schlauderer et al., 2013). Further, active MALT1
was detected in extracts of P/I-stimulated primary blood mono-
nuclear cells (PBMCs) and human T cells from peripheral blood,
clearly underscoring that ABPs can be used to discriminate be-
tween the inactive and active form of MALT1 in lymphocytes
(Figure 2E).
Even though MALT1 was the strongest and only inducible
band in extracts labeled with probe 5, some background signals
were visible. Intriguingly, the signal slightly below 34 kDaChemistry & Biology 22, 129–138, January 22, 2015(Figure 2C, open circle) was reduced
by z-VRPR-FMK, but unaffected by
mepazine or thioridazine treatment. We
assumed cross-reactivity with cysteine
proteases of the cathepsin family, namely
cathepsin B, which migrates at the
respective size and displays a preference
for arginine at the P1 position (Choe
et al., 2006). Indeed, the cell-permeable
cathepsin B inhibitor CA-074Me com-pletely abolished detection of the lower probe 5 signal, while
the detection of the MALT1-ABP complex was unaffected
(Figure 3A). By in vitro protease activity measurements, we
followed up on the possibility that MALT1 tetrapeptide inhibitors
may in fact not only affect MALT1 activity, but also inhibit
cathepsin B. Clearly, probe 5 and also z-VRPR-FMK did not
only inhibit MALT1, but also abrogated cathepsin B activity
even though slightly less efficient (Figure 3B). As expected, cas-
pase 8 activity was not affected by LRSR-AOMK or VRPR-FMK
peptides. Further, neither the noncompetitive MALT1 inhibitor
mepazine, nor the irreversible cathepsin B specific inhibitor
CA-074 showed any cross-inhibition of cathepsin B or MALT1,
respectively. Thus, tetrapeptide probes that target the active
site of MALT1 are also binding to cathepsin B. Since LRSR or
VRPR recognition elements contain unfavorable amino acids
at the P2 position for recognition of cysteine-type cathepsins
(Greenbaum et al., 2002b), improvement of the peptide scaffold
to enhance specificity for MALT1 is hardly possible given the
current knowledge. We therefore set out to optimize the detec-
tion marker.
We synthesized probe 6 with the strong emitting BODIPY
fluorophore to increase signal intensity (Benniston and Copley,
2009). Compared to FITC labeled probe 5, active MALT1 signal
after MALT1 staining with BODIPY labeled probe 6 was
slightly more intense in stimulated Jurkat T cells (Figure 3C).
Cathepsin B labeling in the extracts using probe 6 was slightly
diminished, but in vitro protease inhibition revealed that theª2015 Elsevier Ltd All rights reserved 131
Figure 3. Specificity andCross-Reactivity of
MALT1-ABP in Jurkat T Cells and DLBCL
Cells
(A) MALT1-ABP labeling of Jurkat T cells, pre-
treated with 10 mM CA-074Me.
(B) Impact of indicated compounds on MALT1,
caspase8, and cathepsin B was tested by in vitro
cleavage assays using fluorescent substrates.
Data show the mean ± SD of three independent
experiments.
(C) Comparison of labeling with probe 5 or BODIPY
conjugated probe 6 in Jurkat T cell extracts.
(D) HBL1 cells were incubated with inhibitors
(10 mM each), lysed, and labeled with probe 6.
(E) Probe 6 labeling in extracts can distinguish
between ABC and GCB DLBCL, pretreated
with CA-074Me. Open circle indicates cathepsin
B labeling.
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Detection of Active MALT1 in Cellschange of fluorophore did not reduce cross-reactivity toward
cathepsin B (Figures S2A–S2C). This became even more
evident when we incubated probe 6 in extracts of the ABC
DLBCL cell line HBL1, which displays constitutive MALT1 pro-
tease activity. In HBL1 cell extracts, probe 6 weakly labeled
constitutively active MALT1, confirmed by the sensitivity to
z-VRPR-FMK and mepazine inhibition (Figure 3D). However,
the 30 kDa cathepsin B signal, sensitive to z-VRPR-FMK
and CA-074Me, but not to mepazine treatment, was highly
abundant in HBL1 cells. Also other ABC DLBCL cells show
enhanced signals at this migration using probe 6, indicating
that cathepsin cross-reactivity is a major obstacle of fluores-
cent MALT-ABPs (Figure S2D). To circumvent cathepsin label-
ing, a panel of ABC and GCB (germinal center B cell) DLBCL
cells were pretreated with CA-074Me and subsequently labeled
with probe 6 in whole cell lysates. In all ABC DLBCL cells, a
constitutive MALT1-probe 6 complex was detected in the
absence of any stimulation (Figure 3E). In contrast, the GCB
DLBCL cells showed no MALT1-ABP labeling, which is in line
with previous data that show constitutive MALT1 activity being
restricted to the ABC DLBCL subtype (Ferch et al., 2009; Hail-
finger et al., 2009; Kloo et al., 2011). To test if the MALT1-ABPs
can be used for direct labeling of MALT1 in live cells, we incu-
bated HBL1 cells with increasing concentrations of the probes
and determined their ability to inhibit MALT1-dependent RelB
cleavage (Figures S3A and S3B). Whereas the previously
described MALT1 inhibitor zVRPR-FMK was effectively inhibit-132 Chemistry & Biology 22, 129–138, January 22, 2015 ª2015 Elsevier Ltd All rights reserveing RelB cleavage at 10 or 30 mM, the
LRSR-AOMK based MALT1-ABPs were
unable to inhibit cellular MALT1 activity,
which is most likely due to poor cellular
uptake. Thus, the data indicate that
MALT1-ABPs can be used to discri-
minate between active and inactive
MALT1 in T cells and lymphoma cells.
However, the background staining, the
cross-reaction with cathepsin B, and
the inability to label MALT1 inside the
cell impedes the reliable detection of
the fluorescence labeled MALT1-ABPsin single cell analyses, such as immunohistochemistry or
fluorescence-activated cell sorting.
Active MALT1 Is Highly Modified and Not Restricted
to the CBM Complex
To enhance the selectivity and to boost signal intensity of active
MALT1 detection, we generated biotin-coupled probe 7 (biotin-
K-LRSR-AOMK). A lysine was introduced as a spacer in probe
7 to facilitate the capturing of biotinylated active MALT1 by
streptavidin-coated beads or on microplates. MALT1 and
cathepsins B inhibition by probe 7 was equivalent to all previ-
ously synthesized probes or z-VRPR-FMK (Figure S2C). First,
we evaluated the binding of probe 7 to active MALT1 by pull-
down (PD) using streptavidin-coated beads and subsequent
antibody detection of bound MALT1 (Figure 4). MALT1-probe
7 complexes were exclusively detected in extracts of P/I or
anti-CD3/CD28 stimulated Jurkat T cells (Figures 4A–4C). As
observed for the fluorescent labeled probe 5, MALT1 PD with
probe 7 was blocked by MALT1 inhibitors z-VRPR-FMK or
mepazine (Figure 4B). Cathepsin cross-reactivity was not an
issue in this system, because the secondary detection relied
on MALT1 antibody staining.
Using biotin-coupled probe 7, we addressed the question
how much MALT1 is actually active in stimulated cells and
what fraction of MALT1 represents the active form. Active
MALT1 was efficiently pulled-down using probe 7, and 0.1–
1 mM was also sufficient to completely remove active MALT1d
A B C
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Figure 4. Detection of Active MALT1 by Biotinylated MALT1-ABP
(A) Extracts of Jurkat T cells were incubated with probe 7 (0.01–1 mM),
subjected to PD with streptavidin beads, and analyzed by SDS-PAGE and
western blot. Supernatant was analyzed by probe 6 labeling and fluorescence
scanning.
(B) Jurkat T cells were pretreated with 10 mM inhibitors and PD was performed
as in (A).
(C) Probe 7-PD was performed as in (A) after CD3/28 stimulation.
(D) Probe 7-PD in Jurkat T cells was performed as in (A), detecting the modi-
fied, active MALT1.
(E) Protein complexes from unstimulated and stimulated Jurkat T cells
were separated by size-exclusion chromatography. Pooled fractions were
subjected to probe 7 PD and subsequent MALT1 western blotting. There
was 0.1 mM probe 7 that was used for PDs in (B–E).
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Detection of Active MALT1 in Cellsfrom the extracts of stimulated Jurkat T cells, as revealed by the
lack of residual active MALT1 when labeling the supernatant
after probe 7 PD with the fluorescent MALT1-ABP probe 6
(Figure 4A, lower panel). In fact only a small fraction of cellular
MALT1 was pulled-down by streptavidin-coated beads,
because nearly equal amounts of MALT1 were detected by
western blotting in cell lysates and the supernatants after
streptavidin PD (Figure 4A, middle panels). Thus, only a minor
fraction of cellular MALT1 is activated upon stimulation. By
parallel western blotting of MALT1 after PD and in cell lysates,
we compared the migration of active and total MALT1 (Fig-
ure 4D). Clearly, active MALT1 was heavily modified and
completely shifted to a slower migrating, higher molecular
weight form. This observation is consistent with a previous
study, demonstrating the requirement of mono-ubiquitination
for stimulus-dependent MALT1 activation (Pelzer et al., 2013).
Activation of MALT1 relies on the presence of CARMA1,
because CARMA1 phosphorylation mutant S645A that is unable
to recruit the CBM complex, and subsequently activate NF-kB
upon T cell stimulation, is also not capable to promote MALT1
activation (Figure S4A) (Eitelhuber et al., 2011; Matsumoto
et al., 2005; Sommer et al., 2005). To analyze which protein
complexes contain active MALT1 paracaspase, we performed
gelfiltration experiments from extracts of Jurkat T cells. As noted
earlier, MALT1 is constitutively bound to BCL10 in fractions with
an apparent molecular weight of approximately 150–400 kDa
(Figure S4B) (compare, see Oeckinghaus et al., 2007). The CBM
complex assembled only upon T cell stimulation and migrates
in the fraction A with an apparent molecular weight greater thanChemistry & Biology 22, 1291 Mio Da (Figure S4B). To assess in which protein complexes
active MALT1 is found, we incubated the different fractions with
biotinylated probe 7 (Figure 4E). As expected, active MALT1
was only pulled-down from P/I stimulated Jurkat T cells. Intrigu-
ingly, active MALT1 was detected within the CBM containing
fraction A, but also in the lower molecular weight fractions D
and E that showed MALT1 modification (Figure 4E). Especially
fraction D contained significant amounts of modified MALT1,
indicating the critical impact of ubiquitination for activation.
Taken together, the data reveal that even though CARMA1 is
essential for stimulus-dependent MALT1 activation, fraction-
ation studies coupled to MALT1-ABP detection clearly demon-
strated that active MALT1 is not restricted to the higher order
CBM complex.
Detection of Active MALT1 in Enzyme-Linked
Activity-Sorbent Assay
To further profile a potential usage of biotinylated probe 7 for a
diagnostic type of application, we captured active MALT1-probe
7 complexes on streptavidin-coated plates to perform an ELISA-
type assay that we call enzyme-linked activity-sorbent assay
(ELASA), because it is based on an immobilized activity-sorbent
ABP instead of an immune-sorbent antibody. In this assay,
lysates containing inactive MALT1 are washed off and immobi-
lized active MALT1 is detected by antibody staining in 96-well
microplates. Congruentwith the previous results,MALT1 binding
to streptavidin-coatedplateswas virtually undetectable in resting
cells, and P/I or anti-CD3/CD28 stimulation triggered a massive
increase in relative MALT1 activity in Jurkat T cells, murine
CD4+ T cells, or primary human T cells (Figures 5A–5E). MALT1
activity was strongly reduced upon MALT1 inhibitor treatment,
demonstrating that onlyactiveMALT1wasdetected in theELASA
(Figures 5A and 5C). The high sensitivity of the ELASAwas further
confirmed by showing that 1–10 nanomolar (nM) of probe 7 was
sufficient to obtain a robust signal of active MALT1 from extracts
of 13 107 P/I stimulated Jurkat T cells (Figure 5D). Further, label-
ing of extracts from 2 3 106 primary human T cells with 100 nM
probe 7 resulted in a robust detection of active MALT1, whereas
the gel-based assays in the same experimental setting using the
BODIPY probe 6 reached its detection limit (Figure 5E).
MALT1 ELASA for Detection of Active MALT1 in DLBCL
Patient Biopsies
We asked whether probe 7 could be a reliable tool to distinguish
ABC and GCB DLBCL cell lines based on constitutive MALT1
activity. Indeed, after streptavidin-PD and subsequent western
blot, we detected constitutively active MALT1 exclusively in
ABC, but not in GCB DLBCL cells (Figure 6A). Congruently, the
active MALT1 ELASA revealed a significantly higher level of rela-
tive MALT1 activity in all ABC DLBCL cell lines when compared
toGCBDLBCL cell lines (Figure 6B). RelativeMALT1 activity was
severely reduced after treatment of the cells with mepazine
or z-VRPR-FMK, but not affected by the cathepsin B specific
inhibitor CA074Me. Thus, the MALT1 ELASA can be used to
discriminate cancer cell lines based on the activity of MALT1.
In addition, we tested if the MALT1-ELASA could be used for
cellular inhibitor profiling, and treated the ABC DLBCL cell line
OCI-Ly3 with increasing concentrations of the allosteric MALT1
inhibitor (S-)mepazine or the irreversible MALT1 inhibitor MI-2–138, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 133
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Figure 5. Sensitive and Specific Detection
of Active MALT1 by ELASA
(A) Extracts from inhibitor-treated Jurkat T cells
were incubated with probe 7 (0.1 mM), transferred
to streptavidin-coated plates, and analyzed by
MALT1 antibody detection.
(B) Assay was performed as in (A), but cells were
stimulated with CD3/28.
(C) Assay was performed as in (A) with primary
mouse T cells. Data show the mean ± SD of
three independent experiments (A and B) or two
independent experiments (C).
(D) Jurkat T cells were stimulated or not, lysed,
incubated with different concentrations of probe
7 as depicted, and analyzed as in (A). Data show
the mean ± SD of three independent experiments.
(E) Extracts from primary T cells (2.5 3 106) of two
donors were incubated with either 3 mM probe
6 and analyzed by fluorescence scanning (right
panel) or analyzed as in (A). MALT1 activity is
depicted as arbitrary units (AU).
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Detection of Active MALT1 in Cells(Fontan et al., 2012; Schlauderer et al., 2013) (Figure 6C). Both
compounds inhibited cellular MALT1 at similar concentrations,
with S-mepazine being slightly more potent. Thus, the ELASA
represents a fast and reliable assay tomeasure compound activ-
ity for drug discovery.
We wanted to address if the ELASA could be used to detect
active MALT1 in a clinically relevant diagnostic-type of setting.
For this, we evaluated whether active MALT1 can be detected
in cryo-preserved primary lymphoma tissue from 15 DLBCL
tumor patients that have been classified as ABC DLBCL (eight
biopsies) or GCB DLBCL (seven biopsies) by gene expression
profiling. Cryo-sections were directly lysed, yielding between
200–560 mg total protein amounts for each biopsy. Samples
were split in half and either left untreated or incubated with
z-VRPR-FMK before ELASA (Figure 6D). In general, due to
limited material, the relative MALT1 activities were low in all
DLBCL samples. As the number of tumor cells and absolute
protein amounts from individual tumor tissue varies, we
compared MALT1 activity in the untreated samples to z-VRPR-
FMK inhibited samples. Z-VRPR-FMK treatment led to reduction
in MALT1 activity in five out of eight ABC DLBCL samples, but
only in one out of seven GCB DLBCL samples, suggesting that
MALT1 activity is indeed more often found in ABC DLBCL
tumors. Congruently, there was a significant reduction of
MALT1 activity only in the subset of z-VRPR-FMK treated
ABC, but not the GCB DLBCL samples (Figure 6D). However,
we also observed considerable heterogeneity in MALT1 activity
also within the two DLBCL subentities, because not all ABC
DLBCL samples responded to inhibitor treatment, and also
one GCB DLBCL showed inhibition. In fact, oncogenic lesions
in BCR upstream regulators like CD79B and CARMA1 are not
confined to ABC DLBCL (Compagno et al., 2009; Davis et al.,134 Chemistry & Biology 22, 129–138, January 22, 2015 ª2015 Elsevier Ltd All rights reserve2010; Lenz et al., 2008), suggesting that
MALT1 may also be active in some GCB
DLBCL tumors. To test if expression of
oncogenic mutations derived from the
different subentities is sufficient to acti-vate MALT1, we expressed CARMA1 WT, L244P (ABC derived),
and L225LI (GCB derived) in the GCB DLBCL cell line BJAB (Fig-
ure 6E). Whereas CARMA1 WT failed to induce MALT1 activity,
both oncogenic lesions independent of their DLBCL origin
were enhancing MALT1 activity. Thus, our data reveal that
enhanced MALT1 activity can be detected in primary DLBCL
biopsies and that active MALT1 is predominantly found, but
not restricted to primary ABC DLBCL biopsies.
DISCUSSION
Our study and a parallel report by Hachmann et al. (2014) in this
issue of Chemistry & Biology present MALT1-ABPs as selective
chemical tools for the detection of active MALT1. We show that
MALT1-ABPs can be used for detection of active MALT1 in cell
lines, primary cells, and tumor biopsies. The active and inactive
form of cellular MALT1 can be distinguished by this reliable and
robust methodology. The assay does not rely on MALT1 sub-
strate cleavage, which may differ considerably depending on
individual cell type, tissues, and conditions. We show that fluo-
rescence or biotin coupledMALT1 ABPs can be used to address
important biological questions, e.g., the amount of active
MALT1, as well as its modification or oligomerization status
within cells. In addition, the MALT1 ELASA can detect patholog-
ical MALT1 activity in ABC DLBCL tumor cells.
The fluorophore and biotin-coupled ABPs allow us to directly
show that endogenous MALT1 paracaspase does not rely on
an autocatalytic cleavage reaction, but is active as the full length
protein. Indeed, active MALT1 represents only a very small
fraction of total cellularMALT1.ActiveMALT1 is entirelymodified,
which is in line with a previous study demonstrating the require-
ment of mono-ubiquitination in the C-terminal Ig3 domain ford
A B
C
D E
Figure 6. Classification of ABC and GCB
DLBCL Based on MALT1 Activity Detected
by ELASA
(A) Probe 7-PD (0.1 mM) of untreated DLBCL cells
was performed as in Figure 4A.
(B) ELASA of untreated or inhibitor-treated (10 mM)
DLBCL cell lines was performed as in Figure 5A.
Data show the mean ± SD of three independent
experiments. As one example, significance of dif-
ferences is shown for all ABC DLBCL versus Su-
DHL4 cells as determined by a two-tailed t test
(*p < 0.05 and **p < 0.005).
(C) Cellular inhibitor profiling in OCI-Ly3 cells. Cells
were treated with depicted concentrations of
MI-2 and S-mepazine and ELASA was performed
as in Figure 5A. Data show the mean ± SD of
three independent experiments.
(D) Active MALT1 detection in cryo-preserved
patient tumor samples. Frozen tumor tissue was
lysed with a douncer and syringe, incubated with
z-VRPR-FMK (0.25 mM) or left untreated before
ELASA. Relative MALT1 activity from each
untreated and z-VRPR-FMK treated sample was
measured and directly compared (ABC DLBCL
n = 8; GCB DLBCL n = 7). Significance for
MALT1 activity in untreated to z-VRPR-FMK
treated samples was calculated by a two-tailed
t test (**p < 0.005).
(E) Oncogenic CARMA1 is sufficient to trigger
MALT1 activation. BJAB transduced with
CARMA1 WT or L244P (ABC derived), or L225PI
(GCB derived) were lysed and treated with
z-VRPR-FMK as in (D) and analyzed by ELASA.
Data show the mean ± SD of three independent
experiments. MALT1 activity is depicted as AU.
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MALT1 modifications are critically linked to the initial activation
and also persist during the period that MALT1 is active. In line
with previous studies (Qiao et al., 2013; Rebeaud et al., 2008),
we show that CARMA1 is clearly essential for inducible MALT1
activation. However, cell fractionation experiments demon-
strated that MALT1 activity is not restricted to the higher order
CBM complex that contains the CARMA1-BCL10 filaments
(Qiao et al., 2013). Thus, we conclude that MALT1 is activated
by a kiss and run mechanism, meaning that after transient re-
cruitment to the high molecular weight CBM complex, the active
modified MALT1 is released and can potentially relocate inside
the cell. Indeed, the apparent molecular weight of active MALT1
complexes could correspond to a modified MALT1 dimer bound
to a BCL10monomer or a short oligomer. The fact that MALT1 is
active outside the CBM complex is highly relevant with respect
to substrate recognition and cleavage. It suggests that MALT1
substrates do not need to be recruited to the higher order
CARMA1-BCL10 filaments, which in fact has not been reported
andmay be unlikely for substrates like RelB and Regnase-1 (Hail-
finger et al., 2011; Uehata et al., 2013). We think that other
substrates not connected to the CBM complex will be identified
in the future, and it is intriguing to speculate that active MALT1
could even shuttle between the cytoplasm and the nucleus
to execute its proteolytic functions (Nakagawa et al., 2005).
We show that tetrapeptide inhibitors designed for specific
MALT1 recognition are also inhibiting cathepsin B to a veryChemistry & Biology 22, 129similar extent and possibly other proteasesmay also be affected.
Given the limitations of tetrapeptide recognition with respect
to specificity, we generated a biotin-labeled MALT1-ABP and
established the MALT1 ELASA, which is a highly sensitive and
specific protocol to detect active MALT1. We think ABP labeling
to catch the active enzyme on microplates in combination with
subsequent antibody detection represents a powerful approach
that can be transferred to other proteases, e.g., caspases or
deubiquitinases. Often, the design of specific probes in highly
homologous enzyme families represents a major challenge
(Serim et al., 2012). Indeed, by combining less specific ABPs
that recognize and label a range of proteases with highly
specific antibodies, the ELASA can overcome this restriction
and allow the activity analyses of individual enzymes from
different cells, stimulatory conditions, or cellular compartments.
Importantly, determination of active enzymes by ELASAs can
be implemented to clinical diagnostics just like ELISAs, and
may be much more relevant, because the results reflect the
actual activity rather than just the presence of the enzyme in a
disease setting.
We show that the MALT1 ELASA can foster drug discovery by
determining efficacy ofMALT1 inhibitors.We determinedMALT1
inhibition by the irreversible inhibitor MI2 (Fontan et al., 2012) and
the allosteric inhibitor S-mepazine (Nagel et al., 2012) in ABC
DLBCL cells to show that cellular efficacy of MALT1 inhibitors
with completely different mode of actions can be compared
using the MALT1 ELASA. Further, we demonstrate active–138, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 135
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cell line level, we confirmed that ABC and GCB DLBCL cells
can be discriminated based on the constitutive MALT1 activity
status (Ferch et al., 2009; Hailfinger et al., 2009; Kloo et al.,
2011). A major obstacle for the detection of active MALT1 in
primary lymphoma tissue is the limited availability of cryo-pre-
served material and the varying conditions, e.g., different protein
amounts or different ratios of malignant versus nonmalignant
cells. We therefore directly compared MALT1 activity in un-
treated versus MALT1 inhibitor treated extracts and found that
the majority of ABC DLBCL biopsies were responding, while
most GCB DLBCL samples were not affected. In fact, we also
demonstrate that expression of oncogenic CARMA1 mutants is
sufficient to drive MALT1 activity, and this was independent
whether the mutation originated from an ABC or a GCB DLBCL
tumor patient. Since 6% of all GCB DLBCL tumors carry
somatic mutations in BCR upstream regulators CD79B or
CARMA1 (reviewed in Nagel et al., 2014), MALT1 activity is not
expected to be strictly confined to the ABC DLBCL lineage. Infil-
tration of T cells is often observed in DLBCL and may be associ-
ated with clinical prognosis (Hasselblom et al., 2007). However,
we are not aware of any study that reported significant differ-
ences in T cell frequency or activation between DLBCL subenti-
ties, suggesting that it is rather unlikely that the tumor micro-
environment accounts for the increased MALT1 activity in the
ABC DLBCL samples. Clearly, analyses of larger cohorts of
samples from different lymphoma patients and correlation of
MALT1 ELASA results with oncogenic lesions, other phenotypic
and genotypic tumor markers, as well as patient prognosis will
be required to evaluate whether MALT1 active probes can be a
potential tool to improve lymphoma classification and diagnosis.
Future studies will need to determine in how far detection of
MALT1 activity can facilitate diagnosis and therapeutic decisions
in other lymphoid malignancies. Besides DLBCL, chromosomal
MALT1 translocations and MALT1 activity contribute to MALT
lymphoma (Rosebeck et al., 2011), and MALT1 activity may be
potentially enhanced in mantle cell lymphoma that are sensitive
to the BTK inhibitor ibrutinib (Rahal et al., 2014). Thus, MALT1
activity could serve as an additional biomarker for different lym-
phoma entities or to monitor patient responses to pharmacolog-
ical inhibitors targeting directly MALT1 or upstream regulators.
SIGNIFICANCE
In this work, we designed ABPs to distinguish between the
active and inactive MALT1 paracaspase. MALT1 is a key
regulator of immune cell activation, and proteolytic activity
is induced upon antigen receptor stimulation in B and T lym-
phocytes. The study describes the synthesis and applica-
tion of fluorescence as well as biotin-coupled probes. Our
analyses of the active MALT1 protein underscore that modi-
fication of full length MALT1 is the critical step for MALT1
activation. Furthermore, the data reveal that active MALT1
is found in different cellular complexes and is not restricted
to the high-molecular CBM complex. Given the importance
of MALT1 activity for survival of distinct aggressive lym-
phomas, we established a plate-bound ELASA that allows
sensitive and selective detection of active MALT1. Taken
together, the herein described MALT1-ABPs can be used136 Chemistry & Biology 22, 129–138, January 22, 2015 ª2015 Elsevas powerful tools to study the mechanism of cellular
MALT1 activation, determine cellular efficacy of small mole-
cule MALT1 inhibitors, and to classify lymphomas based on
MALT1 activity status.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
The following antibodies were used: MALT1 (B12), b-Actin (I19), BCL10 (C17)
(all Santa Cruz Biotechnology); FLAG-M2 (Sigma); CARMA1 (1D12), RelB
(C1E4), and MALT1 (2494; ELASA) (all Cell Signaling). Synthesis of mepazine
and S-mepazine is described elsewhere (Schlauderer et al., 2013). The
following reagents were used: z-VRPR-FMK (Alexis Biochemicals), thiorida-
zine (Sigma Aldrich), MI-2 (Tocris Bioscience), CA-074Me andCA-074 (Calbio-
chem), Ac-LRSR-AMC (Peptides International) and Ac-DEVD-AMC (Enzo Life
Science), zRR-AMC (Millipore), Protein G Sepharose (GE Healthcare), murine
IL2 (Roche), and TMB substrate solution (eBioscience). Human cathepsin B
and caspase-8 (BioVision). Streptavidin Agarose Resin (Thermo Scientific)
and Streptavidin coated plates (high binding) (Thermo Scientific).
Cell Culture and Treatment
Jurkat T cells or JPM50.6 were cultured in standard RPMI medium containing
10% fetal calf serum (FCS), 100 U/ml Penicillin/Streptomycin, and 2 mM
Glutamin. DLBCL cell lines (HBL1, TMD8, OCI-Ly3, U2932, RIVA, BJAB,
Su-DHL-4, and Su-DHL-6) were cultured in standard RPMImedium containing
20% FCS, 100 U/ml Penicillin/Streptomycin, and 2 mM Glutamin. OCI-Ly10
cell line was cultured in Iscove’s Modified Dulbecco’s Media containing
20% human serum, 100 U/ml Penicillin/Streptomycin, 2 U/ml heparine, and
50 mM b-mercaptoethanol. Human PBMCs and T cells were purified from
blood treated with heparine (16 U/ml) and centrifuged (300 3 g 10 min room
temperature [RT]) to create the buffy coat; intermediate cell layer was trans-
ferred and purification of cells was performed according to the Dynabeads
Untouched Human T Cells Kit (Invitrogen). Murine CD4+ T cells from spleen
and lymph nodes were purified from C57BL/6 mice with Dynabeads (114.45;
Invitrogen) and cultured as described (Du¨wel et al., 2009). Cells were stimu-
lated either with 200 ng/ml PMA and 300 ng/ml Ionomycin (both Calbiochem)
or CD3/CD28 antibody coligation (humanCD3, 1 mg/ml; humanCD28, 4 mg/ml;
mouse IgG1, 2 mg/ml; and mouse IgG2a, 2 mg/ml; BD Biosciences). Inhibitors
10 mM (z-VRPR-FMK, mepazine, thioridazine, and CA-074Me) were added to
the cells in media for 2 hr, prior to stimulation and ABP labeling.
MALT1-ABP Labeling and PD
For labeling of MALT1 in extracts, Jurkat T cells (1–2 3 107), primary human
PBMCs, or primary human T cells (0.25 or 1 3 107) were lysed in 150 ml coIP
buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 0.2% NP-40, 10% glycerol,
1 mM dithiothreitol (DTT), 10 mM sodium fluoride, 8 mM b-glycerophosphate,
and 300 mM sodium vanadate) without protease inhibitors. DLBCL (3 3 107)
were lysed in 250 ml buffer. After centrifugation (14,000 rotations per minute
[rpm], 10 min, 4C), 100 ml extract (DLBCL, 200 ml) was stained with probe 5
or probe 6 (3 mMend) for 50min at 29C,mixedwith 43 loading dye and boiled.
After protein separation by SDSPAGE, ABP staining was detected by Typhoon
Fluorescence Scanner (FITC laser 488 nanometer [nm]/filter 526 shortpass).
For PD of covalent MALT1-ABP complexes, DLBCL (1–2 3 107) or Jurkat
T cells (1–23 107) were lysed in 500 ml coIP buffer without protease inhibitors,
centrifuged, incubated with biotin-coupled probe 7 (concentration as de-
picted) for 1 hr at RT, then incubated with streptavidin beads for 2 hr at 4C.
Precipitate was washed and analyzed by SDS-PAGE and western blot.
ELASA
Untreated DLBCL (13 107), transducedBJAB (13 107), primary T cells (0.253
107), Jurkat T cells (0.2–13 107), or primary mouse T cells (13 107) (stimulated
or not) were lysed in 300 ml coIP buffer without protease inhibitors, centrifuged,
incubated with probe 7 (concentration as depicted) for 1 hr at RT, then trans-
ferred to streptavidin-coated plates (96-well, clear) and incubated over night
at 4C. After washing in PBS-T (0.05% Tween-20) and blocking with 2%
BSA in PBS-T, detection was performed by incubation with MALT1 primary
antibody (1:800 in 1% BSA in PBS-T; 1 hr, RT) and HRP-coupled secondaryier Ltd All rights reserved
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Detection of Active MALT1 in Cellsantibody (1:1,500 in 1% BSA in PBS-T; 1 hr, RT). There were 3–5 washing
steps with PBS-T that were used after antibody incubation. Signal was
determined after TMB substrate incubation for 10–20 min and subsequent
stop reaction with 1M H2SO4 in a photometer (Bio-Tek) at 450 nm and 570 nm.
MALT1-ELASA in Primary Patient Tumor Tissue
Cryosections of tumor tissue from categorized ABC (eight biopsies) and GCB
(seven biopsies) DLBCL patients (Pfeifer et al., 2013) were lysed in 250 ml buffer
including 250 mM NaCl, 10 mM Tris pH 7.4, 0.5% sodium deoxycholate, 1%
TritonX, 1 mM DTT, 10 mM sodium fluoride, 8 mM b-glycerophosphate, and
300 mM sodium vanadate, homogenized with a douncer and with a syringe
(needle 26 G). After centrifugation (14,000 rpm, 10 min, 4C), protein concen-
tration wasmeasured (range 0.9–2.8mg/ml), extract was divided, and onewas
left untreated and the other was incubated with 0.25 mM z-VRPR-FMK for 1 hr
at 4C. There was 0.1 mM probe 7 that was incubated for 1 hr RT and then
transferred to streptavidin-coated plates and analyzed as described above.
Informed consent was obtained and all studies on primary samples were
approved by the local institutional ethics board of the Charite´ Universita¨tsme-
dizin Berlin (No. EA4/104/11).
Statistical Analysis
The data are displayed as mean ± SD. Significance was determined by
Student’s t test (*p < 0.05 and **p < 0.005).
ACCESSION NUMBERS
The Protein Data Bank (http://www.rcsb.org/pdb/explore/explore.do?
structureId=4i1p) accession number for the MALT1/ABP structure reported
in this paper is 4I1P.
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